STAMFORD, Conn.–(BUSINESS WIRE)–#BigData—Sema4, a patient-centered health intelligence company, today announced the appointment of prominent Wall Street and technology executive R. Martin Chavez to its Board of Directors. Mr. Chavez most recently served in several senior roles for Goldman Sachs, including Chief Information Officer, Chief Financial Officer, and global co-head of the firm’s Securities Division. He was also a member of the firm’s management committee.
“Marty is a leading thinker in harnessing advanced computer science and big data analytics to transform key industries as he successfully did in the global finance arena,” said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. “We are honored that he has joined the Sema4 team and look forward to benefiting from his counsel as Sema4 continues to accelerate the digital healthcare revolution.”
During his time on Wall Street, Mr. Chavez was instrumental in expanding the role of computer scientists in global finance, transforming the way the industry moves capital. He co-founded and served as Chief Executive Officer of Kiodex, acquired by Sungard in 2004, and was Chief Technology Officer and co-founder of Quorum Software Systems.
In addition to Sema4, Mr. Chavez plays an active role in several boards including Paige, an artificial intelligence-driven biomedical technology startup and Recursion, a digital biology company industrializing drug discovery. In May 2020, he was named President of the Harvard Board of Overseers and continues to serve on the Stanford Medicine Board of Fellows and the Board of Trustees of the Institute for Advanced Study. He holds an A.B. (1985) magna cum laude in Biochemical Sciences and an S.M. (1985) in Computer Science from Harvard, and a Ph.D. (1990) in Medical Information Sciences from Stanford.
“Leveraging technology to help people live better, longer, healthier lives is one of the most noble callings of our time,” said Mr. Chavez. “One thing I’ve learned throughout my career is that technology is only as good as the people building and deploying it, and the Sema4 team is top notch. I’m excited to join the board and contribute to this important work of identifying new therapies and making our world a healthier place.”
Mr. Chavez is the latest addition to Sema4’s Board of Directors over recent months following the appointment of Dr. Rachel Sherman, a former senior U.S. Food and Drug Administration (FDA) official. Dr. Sherman spent nearly 30 years with the FDA, serving most recently as Principal Deputy Commissioner of Food and Drugs, the most senior career position at the Agency.
Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.